Jeanette Baker CV

Dynamic Lab Manager and Research Scientist with extensive experience at Stanford University School of Medicine. Proven leadership in training and mentoring graduate students while ensuring compliance in animal protocols and environmental health. Expertise in advanced techniques such as flow cytometry and bioluminescence imaging, driving impactful research outcomes.

• Jayasinghe RG, Hollingsworth D, Schedler NC, Landy E, Boonchalermvichian C, Gupta B, Yan H, Baker J, Dejene B, Weinberg KI, Negrin RS, Mavers M (2025) Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues Cell Rep ;44(5):115587
• Bravo DT, Vaidyanathan S, Baker J, Sinha V, Tsai E, Roozdar P, Kong WW, Atkinson PJ, Patel ZM, Hwang PH, Rao VK, Negrin RS, Wine JJ, Milla C, Sellers ZM, Desai TJ, Porteus MH, Nayak JV (2025) Durable reconstitution of sinonasal epithelium by transplant of CFTR gene corrected airway stem cells. bioRxiv [Preprint].:2025.01.24.634776.
• Boonchalermvichian C, Yan H, Gupta B, Rubin A, Baker J, Negrin RS (2024) Invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies. Front Transplant. 6;3:1353803.
• Maas-Bauer K, Köhler N, Stell AV, Zwick M, Acharya S, Rensing-Ehl A, König C, Kroll J, Baker J, Koßmann S, Pradier A, Wang S, Docquier M, Lewis DB, Negrin RS, Simonetta F 2024) Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells. J Leukoc Biol 115(2):401-409.
• Lohmeyer JK, Hirai T, Turkoz M, Buhler S, Lopes Ramos T, Köhler N, Baker J, Melotti A, Wagner I, Pradier A, Wang S, Ji X, Becattini S, Villard J, Merkler D, Chalandon Y, Negrin RS, Simonetta F. (2023) Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD. Blood. ;141(14):1755-1767
• Ramos TL, Bolivar-Wagers S, Jin S, Thangavelu G, Simonetta F, Lin PY, Hirai T, Saha A, Koehn B, Su LL, Picton LK, Baker J, Lohmeyer JK, Riddle M, Eide C, Tolar J, Panoskaltsis-Mortari A, Wagner JE, Garcia KC (2023) Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo.Blood.16;141(11):1337-1352.
• Vijayan V, Yan H, Lohmeyer JK, Prentiss KA, Patil RV, Barbarito G, Lopez I, Elezaby A, Peterson K, Baker J, Ostberg NP, Bertaina A, Negrin RS, Mochly-Rosen D, Weinberg K, Haileselassie B. (2024) Extracellular release of damaged mitochondria induced by prehematopoietic stem cell transplant conditioning exacerbates GVHD. Blood Adv 23;8(14):3691-3704
• Borna Š, Lee E, Nideffer J, Ramachandran A, Wang B, Baker J, Mavers M, Lakshmanan U, Narula M, Garrett AK, Schulze J, Olek S, Marois L, Gernez Y, Bhatia M, Chong HJ, Walter J, Kitcharoensakkul M, Lang A, Cooper MA, Bertaina A, Roncarolo MG, Meffre E, Bacchetta R. (2023) Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients with FOXP3 mutations.Sci Transl Med. 2023 Dec 20;15(727)
• Xie J, El Rami F, Zhou K, Simonetta F, Chen Z, Zheng X, Chen M, Balakrishnan PB, Dai SY, Murty S, Alam IS, Baker J, Negrin RS, Gambhir SS, Rao J (2022) Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies.ACS Cent Sci.;8(5):590-602
• Hirai T, Lin PY, Ramos TL, Simonetta F, Su LL, Picton LK, Baker J, Lohmeyer JK, Garcia KC, Negrin RS. (2022) IL-2 receptor engineering enhances regulatory T cell function suppressed by calcineurin inhibitor. Am J Transplant. 22(12):3061-3068.
• Hirai T, Mayer AT, Nobashi TW, Lin PY, Xiao Z, Udagawa T, Seo K, Simonetta F, Baker J, Cheng AG, Negrin RS, Gambhir SS (2021) Imaging alloreactive T cells provides early warning of organ transplant rejection. JCI Insight. ;6(13):e145360
• Simonetta F, Alam IS, Lohmeyer JK, Sahaf B, Good Z, Chen W, Xiao Z, Hirai T, Scheller L, Engels P, Vermesh O, Robinson E, Haywood T, Sathirachinda A, Baker J, Malipatlolla MB, Schultz LM, Spiegel JY, Lee JT, Miklos DB, Mackall CL, Gambhir SS, Negrin RS. (2021) Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. Clin Cancer Res.;27(4):1058-1068.
• Maas-Bauer K, Lohmeyer JK, Hirai T, Ramos TL, Fazal FM, Litzenburger UM, Yost KE, Ribado JV, Kambham N, Wenokur AS, Lin PY, Alvarez M, Mavers M, Baker J, Bhatt AS, Chang HY, Simonetta F (2021) Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects. Blood;138(10):858-870.
• Hirai T, Ramos TL, Lin PY, Simonetta F, Su LL, Picton LK, Baker J, Lin JX, Li P, Seo K, Lohmeyer JK, Bolivar-Wagers S, Mavers M, Leonard WJ, Blazar BR, Garcia KC, Negrin RS (2020) Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance J Clin Invest;131(8):e139991
• Alvarez M, Pierini A, Simonetta F, Baker J, Maas-Bauer K, Hirai T, Negrin RS (2021) Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation. Front Immunol:11:614250.
• Simonetta F, Lohmeyer JK, Hirai T, Maas-Bauer K, Alvarez M, Wenokur AS, Baker J, Aalipour A, Ji X, Haile S, Mackall CL, Negrin RS (2021) Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Clin Cancer Res;27(21):6054-6064
• Alvarez M, Simonetta F, Baker J, Morrison AR, Wenokur AS, Pierini A, Berraondo P, Negrin RS. (2020) Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.Front Immunol. 2020 Feb 11;11:7.
• Mavers M, Simonetta F, Nishikii H, Ribado JV, Maas-Bauer K, Alvarez M, Hirai T, Turkoz M, Baker J, Negrin RS. (2019) Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.Front Immunol. 2019 Jul 17;10:1624
• Alvarez M, Simonetta F, Baker J, Pierini A, Wenokur AS, Morrison AR, Murphy WJ, Negrin RS. (2019) Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.JCI Insight. 2019 Jun 18;5(14):e127729
• Pierini A, Iliopoulou BP, Peiris H, Pérez-Cruz M, Baker J, Hsu K, Gu X, Zheng PP, Erkers T, Tang SW, Strober W, Alvarez M, Ring A, Velardi A, Negrin RS, Kim SK, Meyer EH (2017) T cells expressing chimeric antigen receptor promote immune tolerance. JCI Insight. Oct 19;2(20
• Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D'Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J, Negrin R, Gambhir SS (2017) A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res. Jun 1;77(11):2893-2902
• Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan Y, Chen Y, Alvarez M, Strober W, Velardi A, Shizuru JA, Wu JY, Chiba S, Negrin RS. (2017) Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun. May 9;8:15068
• Du J, Paz K, Thangavelu G, Schneidawind D, Baker J, Flynn R, Duramad O, Feser C, Panoskaltsis- Mortari A, Negrin RS, Blazar BR. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood. Jun 8;129(23):3121-3125
• Nishikii H, Kim BS, Yokoyama Y, Chen Y, Baker J, Pierini A, Alvarez M, Mavers M, Maas-Bauer K, Pan Y, Chiba S, Negrin RS. (2016) DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. Blood. Dec 15;128(24):2846-2858
• Pierini A, Strober W, Moffett C, Baker J, Nishikii H, Alvarez M, Pan Y, Schneidawind D, Meyer E, Negrin RS. (2016) TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood. Aug 11;128(6):866-71
• Florek M, Schneidawind D, Pierini A, Baker J, Armstrong R, Pan Y, Leveson-Gower D, Negrin R, Meyer E. (2015) Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease. PLoS One. Dec 22;10(12
• Kurnellas MP, Ghosn EE, Schartner JM, Baker J, Rothbard JJ, Negrin RS, Herzenberg LA, Fathman CG, Steinman L, Rothbard JB. (2015) Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.Proc Natl Acad Sci .Dec 8;112(49):15016-23
• Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, Pan Y, Park CG, Negrin RS. (2015) Treatment with Agonistic DR3 Antibody Results in Expansion of Donor Treg and reduced A Graft Graft Versus Host Disease.
  Blood Jul 23;126(4):546-57
• Pierini A, Colona L, Alvarez M, Schneidawind D, Nishikii H, Baker J, Pan Y, Florek M, Kim BS, Negrin RS.(2015) Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. J
  Immunol May 20. pii: 1402861.
• Baker J, Filatenkov A, Mueller A M.S, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jon S, Shizuru JA, Negrin RS, Engleman EG, Strober S. (2015) Ablative Tumor Radiation Can Change the Tumor
  Immune Cell Microenvironment to Induce Durable Complete Remissions.Clinical Cancer Research, 2015 Apr
  13.
• Schneidawind D, Baker J, Pierini A, Buechele C, Luong RH, Meyer EH, Negrin RS. (2015) Third-party CD4+
  invariant natural killer T cells protect from murine GVHD lethality. Blood. 28;125(22):3491-500
• Pan Y, Leveson-Gower DB, de Almeida PE, Pierini A, Baker J, Florek M, Nishiki Hi, Kim BS, Ke R, Wu, JC ,
  Negrin RS (2015) Engraftment of Embryonic Stem Cells and Differentiated Progeny Following Host
  Conditioning with TLI, ATS, and Regulatory T cells. Cell Rep. pii: S2211-1247(15)00208-9
• Schneidawind D, Pierini A, Alvarez M, Pan Y, Baker J, Buechele C, Luong RH, Meyer EH, Negrin RS. (2014) CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor
  CD4+CD25+FoxP3+ regulatory T cells. Blood. 124(22):3320-8.
• Florek M, Sega EI, Leveson-Gower DB, Baker J, Müller AM, Schneidawind D, Meyer E, Negrin RS(2014)Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Blood 124(11):1832-42.
• Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, ngleman EG, Strober S.(2014) Treatment of 4T1 metastatic breast cancer with combined hypofractionated
  irradiation and autologous T-cell infusion. Radiat Res. 182(2):163-9.
• Colonna L, Florek M, Leveson-Gower DB, Sega EI, Baker J, Smith AT, Negrin RS.(2013) IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation. Biol
  Blood Marrow Transplant. 19(11):1557-65
• Bäuerlein CA, Riedel SS, Baker J, Brede C, Garrote AL, Chopra M, Ritz M, Beilhack GF, Schulz S, Zeiser R,
  Schlegel PG, Einsele H, Negrin RS, Beilhack A. (2013) A diagnostic window for the treatment of acute graft-
  versus-host disease prior to visible clinical symptoms in a murine model. BMC Med. 21;11:134.
• Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, Negrin
  RS.(2012) Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119(24):5758-68
• Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS.(2011) Rapamycin and IL-2 reduce lethal
  acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+
  regulatory T cells. Blood 118(8):2342-50
• Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S,
  Benjamin JE, Weng WK, Negrin RS. (2011 )Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 17(11):1679-87
• Leveson-Gower DB, Olson JA, Sega EL. Leong RH, Baker J, Zeiser R, Negrin RS.(2011) Low doses of natural
  killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood
  117(11): 3220-9.
• Dutt S, Baker J, Kohrt HE, Kambham N, Sanyal M, Negrin RS, Strober S. (2011). CD8+CD44hi but not CD4+CD44hi memory T cells mediate potent graft antilymphoma activity without GVHD. Blood 117(11): 3230-9.
• Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS (2010). NK cells mediate reduction of GVHD binhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 115(21):4293-301.
• Nador RG, Hongo D, Baker J, Yao Z, Strober S (2010). The changed balance of regulatory and naive T cells promotes tolerance after TLI and anti-T-cell antibody conditioning. Am J Transplan, 10: 262-72.
• Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS. (2008) In vivo trafficking
  and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity
  Blood.112(6):2563-74.
• Beilhack A, Schulz S, Baker J, Beilhack GF, Nishimura R, Baker EM, Landan G, Herman EI, Butcher EC,
  Contag CH, Negrin RS. (2008) Prevention of acute graft-versus-host disease by blocking T-cell entry to
  secondary lymphoid organs. Blood, 111(5):2919-28.
• Chan JK, Hamilton C, Anderson EM, Cheung MK, Baker J, Husein A, Teng NN, Kong CS, Negrin RS. (2007)
  A novel technique for the enrichment of primary ovarian cancer cells. Am J Obstet Gynecol (5):507.e1-5
• Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. (2007) Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood, 110(13):4588-98.
• Zeiser R, Nguyen VH, Beilhack A, Buess M, Schultz S, Baker J, Contag CH, Negrin RS. (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. 108(1):390-9.
• Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS. (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine- induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12(6):1859-67.
• Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS. (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-
• Karimi, M; Cao, TM; Baker, J; Verneris, MR; Soares; L; Negrin RS. (2005) Silencing human NKG2D, DAP10
  and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 175(12):7819-28.induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12(6):1859-67.
• Schimmelpfennig, CH; Schulz, S; Arber, C; Baker, J; Tarner, I; McBride, J; Contag, CH; Negrin, RS. (2005) Ex
  vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone
  marrow transplantation. Ame J of Pathology; 167(5):1321-31.
• Swijnenburg, RJ; Tanaka, M; Vogel, H; Baker, J; Kofidis, T; Gunawan, F; Lebl, DR; Caffarelli, AD; de Bruin, JL; Fedoseyeva, EV. (2005). Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation, 112(9).I166-72.
• Beilhack, A; Schulz, S; Baker, J; Beilhack, GF; Wieland, CB; Herman, EI; Baker, EM; Cao, YA; Contag, CH;
  Negrin, RS. (2005) In vivo analyses of early events in acute graft-versus-host disease reveal sequential
  infiltration of T-cell subsets. Blood, 106(3):1113-22
• Verneris, MR; Karami, M; Baker, J; Jayaswal, A; Negrin, RS. (2004) Role of NKG2D signaling in the
  cytotoxicity of activated and expanded CD8+ T cells. Blood, 103(8): 3065-72.
• Verneris, MR; Baker, J; Edinger, M; Negrin, RS. (2002) Studies of ex vivo activated and expanded CD8+ NK-T
  cells in humans and mice. Journal of Clinical Immunology, 22(3):131-36
• Baker, J; Verneris, MR; Ito, M; Shizuru, JA; Negrin, RS (2001) Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production Blood 97(10):2923-31.
• Geiler, CR; Baker, J; Wells, S; Schlegel, PG; Chao, NJ (1996) Purging peripheral blood progenitor cells with
  4-hydroperoxycyclophosphamide (4-HC) CANCER RESEARCH THERAPY & CONTROL 5(1):.23-27.
• Fernandez,LP; Schlegel, PG; Baker, J; Chen, YF; Chao, NJ (1995) Does Thalidomide affect Il-2 response and production, EXPERIMENTAL HEMATOLOGY, 23(12):1324-34.